However, the COVER trial, which succeeded the ACR guidelines, specifically evaluated the immunogenicity of COVID-19 vaccine boosters and found that suspending abatacept (and JAKi, TNFi, and IL-17 therapies) did not significantly improve immunogenicity and was associated with an increased risk for disease flares in patients with RA and psoriatic arthritis [91]. This evidence concerns the gene IL17A and COVID-19.